Skip to content
TrialScanner

NCT07784959

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Phase 1RecruitingNVCTLead

Registry record

Lead sponsor
Nuvectis Pharma, Inc.
Conditions
ALK Positive; ALK Positive Non-small Cell Lung Cancer; NSCLC; ALK+ Non-Small-Cell Lung Carcinoma
Primary completion
Aug 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07784959 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.